MindWalk Holdings (HYFT) Change in Inventory (2023 - 2026)
MindWalk Holdings (HYFT) posted quarterly Change in Inventory of -$2188.5 for Q2 2026, up 97.29% year-over-year from -$1109.3 in Q2 2025, and down 107.41% quarter-over-quarter from $29543.4 in Q1 2026.
MindWalk Holdings (HYFT) Change in Inventory (2023 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Change in Inventory for 4 consecutive years, with -$2188.5 the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Inventory rose 97.29% year-over-year to -$2188.5; the TTM figure through Apr 2026 stood at -$38825.3 (down 138.21% YoY), while the FY2026 annual figure was -$38663.8, down 139.03% from the prior year.
- Change in Inventory eased to -$2188.5 in Q2 2026 per HYFT's latest filing, from $29543.4 in the prior quarter.
- Across five years, Change in Inventory topped out at $303120.8 in Q2 2024 and bottomed at -$323998.0 in Q1 2024.
- Historically, Change in Inventory has averaged -$12315.8 across 4 years, with a median of -$27978.0 in 2023.
- On a YoY basis, Change in Inventory climbed as much as 629.93% in 2024 and fell as far as 530.52% in 2024.
- MindWalk Holdings' Change in Inventory stood at -$14749.9 in 2023, then slumped by 530.52% to -$93000.7 in 2024, then soared by 94.57% to -$5046.2 in 2025, then surged by 56.63% to -$2188.5 in 2026.
- Business Quant data shows HYFT's Change in Inventory at -$2188.5 in Q2 2026, $29543.4 in Q1 2026, and -$5046.2 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 28.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 47.15 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,188.52 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -280,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 12.97 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -2,188.52 |
| Apr 30, 2026 | -2,188.52 |
| Jan 31, 2026 | 29,543.36 |
| Jan 31, 2026 | 29,543.36 |
| Oct 31, 2025 | -5,046.15 |
| Oct 31, 2025 | -5,046.15 |
| Jul 31, 2025 | -61,133.97 |
| Jul 31, 2025 | -61,133.97 |
| Apr 30, 2025 | -80,813.80 |
| Apr 30, 2025 | -80,813.80 |
| Jan 31, 2025 | 57,058.58 |
| Jan 31, 2025 | 57,058.58 |
| Oct 31, 2024 | -93,000.67 |
| Oct 31, 2024 | -93,000.67 |
| Jul 31, 2024 | 218,363.28 |
| Jul 31, 2024 | 218,363.28 |
| Apr 30, 2024 | 303,120.83 |
| Apr 30, 2024 | 303,120.83 |
| Jan 31, 2024 | -323,998.01 |
| Jan 31, 2024 | -323,998.01 |